Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PointBreak: Pemetrexed vs Paclitaxel Regimens in Advanced Nonsquamous NSCLC
NCT00762034Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Dec 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00762034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00762034.